A snapshot of the prevalence of endocrine disorders in pregnancies complicated by COVID-19: A narrative review with meta-analysis.

BACKGROUND: Some maternal characteristics indicate worse prognosis in pregnancies with COVID-19. OBJECTIVE: Describe prevalence of endocrine disorders in pregnancies with COVID-19, and impact on maternal outcomes. SEARCH STRATEGY: \u0027pregnancy\u0027 and \u0027COVID-19\u0027. SELECTION: PubMed, Embase, medRxiv and Cochrane worksheet; from February to July 2020. DATA COLLECTION AND ANALYSIS: articles describing endocrine disorder in pregnancies with and without COVID-19; we performed meta-analyses of prevalence using random-effect models and estimated relative risk and 95% CI of maternal outcomes relative to presence of endocrine disorders. MAIN RESULTS: Articles included (n=141) were divided in three datasets: individual (119 articles, 356 women), case series (17 articles, 1064 women) and national registries (7 articles, 10 178 women). Prevalence of obesity ranged from 16% to 46; hyperglycemia in pregnancy (HIP), from 8% to 12%. In dataset 1, HIP and obesity were risk factors for severe disease in crude and age adjusted models, although not for intensive care unit admission. In data from two national registries, risk of dying was 5.62 (95% CI 0.30-105.95) in women with diabetes and 2.26 (95% CI 1.03-4.96) in those with obesity. CONCLUSION: Obesity and HIP were prevalent in pregnancies with severe COVID-19.